Tests in vitro and in vivo on mice provided very clear-cut results, and modelling demonstrates that the treatment targets at least six different points of tumor metabolism.
Gene therapy, a technique that selectively attacks a tumor, might provide hope in the fight against this type of deadly cancer, for which surgery is practically impossible and chemo- and radiotherapy are ineffective against very aggressive recurrences.
The following animation demonstrates the proposed mechanism of action for Tocagen’s lead cancer-selective gene therapy product candidate, Toca 511 & Toca FC, and is based primarily on preclinical data.
Tocagen is developing broadly applicable, cancer-selective immunotherapy treatments for cancer, including high grade glioma, a type of brain cancer. The company’s lead product combines Toca 511 with Toca FC.
The therapeutic regimen involves two discrete steps with Toca 511 given first followed by treatment with Toca FC.
A NBC reporter interviews patient Berm, who was given a prognosis of six months after being diagnosed with recurrent brain cancer, but two years later was still doing well.
He shares more about his quality of life and how the treatment makes him feel.
Dr. David Piccioni, neuro-oncologist at UC San Diego also explains how the viral therapy is designed to work.